Merck Acquires Bio-Techne for $11.3 Billion
Merck (MRK) announced the acquisition of Bio-Techne, a life sciences and diagnostics company, in an all-cash deal valued at $11.3 billion. The transaction is expected to close in the first half of 2026, subject to regulatory approvals.
AAPLApple Inc.
MUMicron Technology, Inc.
JPMJP Morgan Chase & Co.
GSGoldman Sachs Group, Inc. (The)
MSMorgan Stanley
MRKMerck & Company, Inc.Key Numbers
Merck (MRK) announced today the acquisition of Bio-Techne in an all-cash deal valued at $11.3 billion, or $120 per share. The deal aims to strengthen Merck's presence in the life sciences and diagnostics market, expanding its portfolio of products and services.
Deal Details
| Item | Details |
|---|---|
| Total Value | $11.3 billion |
| Per Share Price | $120 in cash |
| Premium | Not disclosed |
| Payment Method | All cash |
| Regulatory Approvals | Subject to customary approvals |
| Expected Close | First half of 2026 |
Rationale
Merck seeks to:
- Strengthen its position in the fast-growing life sciences and diagnostics market.
- Leverage Bio-Techne's innovative technologies in recombinant proteins and antibodies.
- Expand its product and service offerings in research and diagnostics.
Regulatory Challenges
The deal is expected to undergo antitrust review in the US and Europe. No regulatory objections have been raised so far, but large healthcare deals often face close scrutiny.
Impact on Stocks
Bio-Techne shares rose over 15% in midday trading Thursday, while Merck's stock moved modestly. Analysts expect the deal to boost Merck's life sciences revenue but may increase its debt burden in the short term.
Frequently Asked Questions
Found this useful? Share it